Cervical cancer is a malignant gynecologic disease and is predominantly caused by infection with high-risk human papillomavirus. It is a major cause of cancer-related illness and death, and prevention efforts include cervical screening and HPV vaccination. Mechanistically, recent work highlights metabolism-immunity interactions, with a single-cell/spatial transcriptome study identifying 758 differential genes, 453 overlapping CTD cervical cancer targets, and 20 hub genes, alongside activation of calcium signaling, neuroactive ligand-receptor interaction, and glycolysis/TCA pathways. The disease is also being reshaped by immunotherapy in locally advanced and recurrent/metastatic settings, including checkpoint blockade and combination regimens. Prognostic and biomarker studies include an intratumoral heterogeneity-corrected signature and HPV16 integration hotspot analyses, while FAM83D promotes EMT and metastasis via GSK3β/Snail signaling.
Metabolism and target discovery
- A single-cell and spatial transcriptome study of cervical cancer identified 758 differential genes, with 453 overlapping cervical cancer targets in CTD and 20 hub genes; enriched pathways included calcium signaling, neuroactive ligand-receptor interaction, and glycolysis/TCA. (PMID:41283998)
- matrine was investigated as a potential therapeutic intervention in a metabolism-immunity interaction network for cervical cancer. (PMID:41283998)
- The same 2025 study used metabolism-immunity analysis to support therapeutic target discovery in cervical cancer. (PMID:41283998)
Immunotherapy and advanced disease
- immune checkpoint inhibitors were approved for locally advanced cervical cancer and recurrent/metastatic disease, reflecting a major shift in the therapeutic landscape. (PMID:41958269)
- pembrolizumab and cemiplimab were both incorporated into cervical cancer treatment and associated with improved survival. (PMID:41958269)
- Low pd l1 expression was linked to limited long-term efficacy in cervical cancer immunotherapy. (PMID:41958269)
- A case report described recurrent/metastatic cervical cancer treated with ivonescimab plus albumin bound paclitaxel. (PMID:42012232)
Biomarkers, prognosis, and viral integration
- intratumoral heterogeneity corrected prognostic signature was developed for cervical cancer prognosis in an integrated multi-omics analysis. (PMID:41938365)
- clic5 was proposed as a potential biomarker for HPV-driven cervical cancer, with CLIC5 identified as a recurrent hotspot of HPV16 integration. (PMID:41923498)
- Cervical cancer was highlighted as a disease context for HPV16 integration hotspot analysis and biomarker discovery. (PMID:41923498)
Invasion, metastasis, and molecular mechanisms
- fam83d facilitates epithelial-mesenchymal transition and metastasis of cervical cancer. (PMID:41882663)
- FAM83D acts through interaction with GSK3β and inactivation of GSK3β/stabilization of Snail signaling. (PMID:41882663)
- The disease was also used as the context for studying metastasis-related molecular mechanisms in multi-omics and target-discovery work. (PMID:41938365)
Prevention and supportive care
- cervical screening is part of prevention efforts for cervical cancer, alongside HPV vaccination uptake initiatives. (PMID:41224642)
- A review on gynecologic oncology discussed peptides as next-generation immunotargeting agents, including in cervical cancer. (PMID:41930712)
- Immune checkpoint therapy can be complicated by autoimmune hemolytic anemia, reported in a cervical cancer patient receiving PD-1 therapy. (PMID:41944848)